Genentech, Inc.

Vertex Pharmaceuticals, Inc.

Merck Frosst Canada & Co.

Boehringer Ingelheim International Gmbh

Merck Frosst Company

Merck Sharp + Dohme Corp.

Merck Frosst Canada, Inc.

Xenon Pharmaceuticals Inc.

Merck Canada Inc.

Claudio F Sturino

Carl Berthelette

Zhaoyin Wang

Lianhai Li

Nicolas Lachance

Huifen Chen

Michel Gallant

Claude Dufresne

Matthew Volgraf

Elisia Villemure

Yeeman K Ramtohul

Lea Constantineau-Forget

Robin Larouche-Gauthier

Francis Beaumier

Luce Lépissier

Jack Alexander Terrett

Jean-Eric Lacoste

Janek Szychowski

Martin Déry

Chantal Grand-Maître

Mark Thomas Miller

Jinglan Zhou

Sara Sabina Hadida Ruah

Tiansheng Wang

Yongxin Han

Francois Maltais

Daniel P Sutherlin

Brian Ledford

Jingrong Cao

Jon H Come

Thomas Cleveland

Martin Duplessis

Clint A James

Timothy Richard Coon

Marc Labelle

Prasuna Paraselli

Brett C Bookser

Jeremy J Clemens

Thumkunta Jagadeeswar Reddy

Suganthini S Nanthakumar

Kwong Wah Lai

Jason Burch

Steven McKerrall

Warren A Dorsch

Michael Boyd

Elaine B Krueger

Ramsay Beveridge

Minson Baek

Patrick Deroy

Leslie A Dakin

Timothy J Senter

Jean-Philippe Leclerc

Alexandre Lemire

Liang Zhao

Anne Fortier

Camil Sayegh

Olivier Nicolas

Louis Morency

Martin Tremblay

Julie Farand

Lee Fader

Joannie Minville

Francois Denis

Julie Laterreur

William Schulz Bechara

Robert N Young

Luc J Farmer

Pierre Louis Beaulieu

Christiane Yoakim

Daniel Guay

Peter Grootenhuis

Peter Diederik Jan Grootenhuis

Bruno Simoneau

Teddy Halmos

Birong Zhang

Anne-Marie Faucher

Michael Scott Wilson

Patrick Lacombe

John Scheigetz

Lino J Valdez

Constantin G Yannopoulos

Michael F T Koehler

Paul John Edwards

Bingcan Liu

Vito Melillo

Christian Beaulieu

Peter Andrew Smith

Philippe Bergeron

Monica Bubenik

Dwight Macdonald

Frederic Vallee

Sebastien Morin

Renee Aspiotis

Zhiguo Liu

Julien Martel

Eric Malenfant

Jonathan Boudreault

Wenfeng Liu

Stephanie Lessard

Sébastien Morin

This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and pharmaceutical compositions, and processes for making such modulators.

Modulators of cystic fibrosis transmembrane conductance regulator

The disclosure provides at least one compound, deuterated derivative, or pharmaceutically acceptable salt chosen from compounds of formula (I), deuterated derivatives thereof, and pharmaceutically acceptable salts of any of the foregoing, compositions comprising the same, and methods of making and using the same, including use in treating APOL1 mediated kidney disease.

Inhibitors of APOL1 and methods of using same

The invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof wherein A, X, R, Rand n are as defined herein. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.

Oxadiazole transient receptor potential channel inhibitors

The disclosure provides at least one entity chosen from compounds of Formula (I)

The invention relates to methods of using compounds formula I: and pharmaceutically acceptable salts thereof wherein A, X, R, Rand n are as defined herein. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.

Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidases SpsB and/or LepB, an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.

Macrocyclic broad spectrum antibiotics

The invention provides benzene sulfonamides and pharmaceutically acceptable salt thereof that are useful as sodium channel blockers for the treatment of, for example, pain. The following compound is illustrative: 

Therapeutic compounds and methods of use thereof

The invention provides a compound of formula I: or a pharmaceutically acceptable salt thereof, wherein the variables X, Y&#x2014;Y, R, R, R, R, and Het have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

The present invention relates to compounds useful as inhibitors of the PAR-2 signaling pathway. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of GPCRs in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such GPCRs; and the comparative evaluation of new inhibitors of the PAR-2 signaling pathway. The compounds of this invention have formula I: wherein the variables are as defined herein.

Imidazopyridazines useful as inhibitors of the PAR-2 signaling pathway

Compounds of formula (I) and pharmaceutical compositions thereof: wherein AAand Aare each independently selected from the group consisting of N and CR, wherein Ris an optionally substituted heterocyclyl or an optionally substituted &#x2014;(C)alkyl-heterocyclyl, Ris an optionally substituted aryl or an optionally subsisted heteroaryl, Ris an optionally substituted aryl, an optionally substituted heterocyclyl or an optionally substituted heteroaryl, useful as an inhibitor of HIV replication. 

Inhibitors of HIV replication

The invention is directed to &#x3b2;-carboline sulphonylurea derivatives as EP4 receptor antagonists useful for the treatment of EP4 mediated diseases or conditions, such as acute and chronic pain, inflammation, osteoarthritis, and rheumatoid arthritis. Pharmaceutical compositions and methods of use are also included.

Beta carboline sulphonylurea derivatives as EP4 receptor antagonists

Compounds of formula (I): wherein R, R, A, A, A, A, X and Y are as defined herein, are useful as inhibitors of HIV replication.

The invention is directed to naphthalene and quinoline sulfonylurea derivatives as EP4 receptor antagonists useful for the treatment of EP4 mediated diseases or conditions, such as acute and chronic pain, osteoarthritis, rheumatoid arthritis and cancer. Pharmaceutical compositions and methods of use are also included.

Naphthalene and quinoline sulfonylurea derivatives as EP4 receptor antagonists

Growing community of inventors

L′ile-Bizard, Canada

Claudio F Sturino